SCHEMBL25840779

SCHEMBL25840779

Cc1ccc(NC(=S)NCCS(=O)(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 6/20 0.50
KMT2A Q03164 6/20 0.50
MAPT P10636 5/20 0.50
HTT P42858 4/20 0.50
LMNA P02545 2/20 0.50
ALDH1A1 P00352 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
ALOX12 P18054 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
RECQL P46063 1/20 0.48
QPCT Q16769 1/20 0.48
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25840781 0.92 RECQL (0.56) SMN1; SMN2MEN1KMT2AMAPTHTT
SCHEMBL25840772 0.85 SMN1; SMN2 (0.58) SMN1; SMN2MEN1KMT2AHTTLMNA
SCHEMBL29043442 0.83 RECQL (0.53) SMN1; SMN2MEN1KMT2AMAPTHTT
SCHEMBL25840778 0.83 CA12 (0.61) SMN1; SMN2MEN1KMT2AALDH1A1NPC1
SCHEMBL23328400 0.81 CDK1 (0.67) SMN1; SMN2MEN1KMT2AMAPTHTT
SCHEMBL25517525 0.78 CYP1A2 (0.72) SMN1; SMN2MEN1KMT2AMAPTHTT
SCHEMBL11772198 0.78 CDK1 (0.63) SMN1; SMN2MEN1KMT2AMAPTHTT
SCHEMBL25840780 0.77 ALDH1A1 (0.59) SMN1; SMN2HTTALDH1A1NPC1RAB9A
SCHEMBL9100229 0.76 MAPT (0.59) MEN1KMT2AMAPTHTTLMNA
SCHEMBL17982696 0.76 LMNA (0.65) SMN1; SMN2MEN1KMT2AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701333-B2 Antibacterial compounds Kent Innovation & Enterprise (GB) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701333-B2 Antibacterial compounds ARF1, ARL1, TLR1 SMN1; SMN2 3087/4885MEN1 1300/4885KMT2A 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.